Abstract
Rho GDP-Dissociation Inhibitors (RhoGDIs) are important regulators of the Rho family of small GTPases. The expression of RhoGDIs is altered in a variety of cancers and they have been shown to mediate several processes during tumorigenesis and cancer progression. Using examples of RhoGDI-mediated signaling and expression patterns in endothelial cells as well as pancreatic, breast, and bladder cancer, the multitude of potential cancer therapeutic targets presented by a better understanding of their function is illustrated. Several novel therapeutic strategies are proposed for intervening in RhoGDI signaling, and potential complications arising from their implementation are discussed.
Published by Elsevier Ltd.
Publication types
-
Research Support, N.I.H., Extramural
-
Review
MeSH terms
-
Antineoplastic Agents / pharmacology
-
Breast Neoplasms / drug therapy
-
Breast Neoplasms / metabolism
-
Female
-
Guanine Nucleotide Dissociation Inhibitors / antagonists & inhibitors
-
Guanine Nucleotide Dissociation Inhibitors / metabolism*
-
Humans
-
Neoplasm Proteins / antagonists & inhibitors
-
Neoplasm Proteins / metabolism
-
Neoplasms / drug therapy
-
Neoplasms / metabolism*
-
Pancreatic Neoplasms / drug therapy
-
Pancreatic Neoplasms / metabolism
-
Signal Transduction / drug effects
-
Signal Transduction / physiology
-
Urinary Bladder Neoplasms / drug therapy
-
Urinary Bladder Neoplasms / metabolism
-
rho Guanine Nucleotide Dissociation Inhibitor alpha
-
rho-Specific Guanine Nucleotide Dissociation Inhibitors
Substances
-
ARHGDIA protein, human
-
Antineoplastic Agents
-
Guanine Nucleotide Dissociation Inhibitors
-
Neoplasm Proteins
-
rho Guanine Nucleotide Dissociation Inhibitor alpha
-
rho-Specific Guanine Nucleotide Dissociation Inhibitors